Silexion Therapeutics

(NASDAQ) SLXN

Current Price$2.70

Market Cap$2.81M

Since IPO (2021)-100%

5 Year-100%

1 Year-98%

1 Month-47%

Silexion Therapeutics Financials at a Glance

Market Cap

$2.81M

Revenue (TTM)

$0.00

Net Income (TTM)

-$12.91M

EPS (TTM)

-$94.56

P/E Ratio

-0.03

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$2.70

Volume

1,272

Open

$2.67

Price

$2.70

Volume

1,272

Open

$2.67

Previous Close

$2.70

Daily Range

$2.67 - $2.70

52-Week Range

$2.31 - $223.60

Estimated Earnings Date

Aug 11, 2026

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$2.70

Volume

1,272

Open

$2.67

Previous Close

$2.70

Daily Range

$2.67 - $2.70

52-Week Range

$2.31 - $223.60

Estimated Earnings Date

Aug 11, 2026

SLXN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Silexion Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Ilan Hadar, MBA

Website

silexion.com

Headquarters

Jerusalem, 9112001, IL

SLXN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-516.87%

Return on Capital

378.77%

Return on Assets

-280.53%

Earnings Yield

-33.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.81M

Shares Outstanding

1.06M

Volume

1.27K

Avg. Volume

639.06K

Financials (TTM)

Gross Profit

-$6.00K

Operating Income

$10.53M

EBITDA

-$12.89M

Operating Cash Flow

-$12.01M

Capital Expenditure

-$3.00K

Free Cash Flow

-$12.02M

Cash & ST Invst.

$2.41M

Total Debt

$436.00K

Silexion Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$2.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$2.81M

N/A

Market Cap/Employee

$255.64K

N/A

Employees

N/A

Net Income

-$2.73M

-57.5%

EBITDA

-$2.73M

-58.6%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$2.41M

-60.8%

Total Debt

$436.00K

-87.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$251.00K

-92.5%

Short Term Debt

$185.00K

+19.4%

Return on Assets

-2.81%

N/A

Return on Invested Capital

19.43%

N/A

Free Cash Flow

-$3.65M

-48.3%

Operating Cash Flow

-$3.65M

-48.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ENVBEnveric Biosciences, Inc.

ENVBEnveric Biosciences, Inc.$1.45-3.33%

SLRXSalarius Pharmaceuticals, Inc.

SLRXSalarius Pharmaceuticals, Inc.$0.84+29.23%

LIPOLipella Pharmaceuticals Inc.

LIPOLipella Pharmaceuticals Inc.$0.13+0.00%

PTIXProtagenic Therapeutics, Inc.

PTIXProtagenic Therapeutics, Inc.$0.23-34.29%

SCNIScinai Immunotherapeutics Ltd.

SCNIScinai Immunotherapeutics Ltd.$0.27-0.59%

ONCOOnconetix, Inc.

ONCOOnconetix, Inc.$0.96-11.53%

INDPIndaptus Therapeutics, Inc.

INDPIndaptus Therapeutics, Inc.$3.03+3.06%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ABTCAmerican Bitcoin

ABTCAmerican Bitcoin$8.43-0.10%

NOKNokia

NOKNokia$12.07-0.07%

NUNu Holdings

NUNu Holdings$13.60+0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$39.95+0.05%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$73.35-0.05%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$12.30-0.15%

CLROClearOne

CLROClearOne$6.48+1.01%

Questions About SLXN

What is the current price of Silexion Therapeutics?

Silexion Therapeutics is trading at $2.70 per share.

What is the 52-week range for Silexion Therapeutics?

Over the past 52 weeks, Silexion Therapeutics has traded between $2.31 and $223.60.

How much debt does Silexion Therapeutics have?

As of the most recent reporting period, Silexion Therapeutics reported total debt of $1.99M.

How much cash does Silexion Therapeutics have on hand?

Silexion Therapeutics reported $2.44M in cash and cash equivalents in its most recent financial results.

What is Silexion Therapeutics’s dividend yield?

Silexion Therapeutics does not currently have a dividend yield.

Silexion Therapeutics

Silexion Therapeutics Financials at a Glance

SLXN News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Silexion Therapeutics

SLXN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Silexion Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About SLXN

What is the current price of Silexion Therapeutics?

What is the 52-week range for Silexion Therapeutics?

How much debt does Silexion Therapeutics have?

How much cash does Silexion Therapeutics have on hand?

What is Silexion Therapeutics’s dividend yield?

Premium Investing Services